Overview

GRAVITAS-119: Itacitinib in Combination With Calcineurin Inhibitor-Based Interventions for the Prophylaxis of Graft-Versus Host Disease

Status:
Terminated

Trial end date:
2021-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the impact and safety of itacitinib in combination with calcineurin inhibitor (CNI)-based interventions for the prophylaxis of graft-versus-host-disease (GVHD).

Phase:

Phase 1

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Calcineurin Inhibitors